Format

Send to

Choose Destination
J Nephrol. 2015 Oct;28(5):641-5. doi: 10.1007/s40620-015-0173-5. Epub 2015 Feb 25.

Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management.

Author information

1
Nephrology Department, Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain. desousa@clinic.ub.es.
2
Nephrology Department, Hospital Clinic, Calle Villarroel, 170, 08036, Barcelona, Spain.
3
Histopathology Department, Hospital Clinic, Barcelona, Spain.
4
Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28040, Madrid, Spain.

Abstract

Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued after complete remission and resolution of the precipitating cause, especially in patients with a low-risk genetic profile.

KEYWORDS:

Eculizumab; Hemolytic uremic syndrome; Post-partum; Pregnancy

PMID:
25712233
DOI:
10.1007/s40620-015-0173-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center